Characterizing immune features of thymic epithelial tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The IMMUNO-TET trial aims to evaluate the immune environment and molecular characteristics of localized thymic epithelial tumors (TETs) in patients undergoing thymectomy or thymomectomy. This prospective study involves collecting blood samples and tumor specimens during surgery for comprehensive analysis, including flow cytometry and RNA sequencing. Additionally, the feasibility of developing patient-derived xenografts from TETs will be explored to test potential therapeutic agents. The study will follow patients through their surgical journey and post-operative care to assess immune responses and molecular profiles.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patient with suspicion of localised thymic epithelial tumour.
2. Age ≥ 18 years.
3. Treatment-naïve patient for this disease.
4. Patient with an indication for thymectomy and thymomectomy in one of the partner centers.
5. Signed informed consent form of the patient.

Exclusion Criteria:

1. Neoadjuvant chemotherapy.
2. No social security affiliation.
3. Person under legal protection.
4. Other neoplasia in progress or cured within the last 3 years (except for operated carcinoma in situ).

Where it's running

• Institut Curie Paris
  Paris, France Recruiting
• Institut Mutualiste Montsouris
  Paris, France Recruiting
• Hôpital FOCH
  Suresnes, France Recruiting

Study contacts

• Study coordinator: Nicolas GIRARD, MD
• Email: nicolas.girard2@curie.fr
• Phone: 0156245539

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using enteral (tube) feeding as recommended for adults with cancer.

  This project will see how well enteral (tube) feeding recommendations are followed by adults hospitalized for cancer who need enteral nutrition.

  Recruiting Institut Curie · Paris · NCT07571564

• Home-capillary blood sampling to monitor CDK4/6 inhibitors in breast cancer

  This study tests whether fingertip capillary samples collected at home can reliably measure drug levels for breast cancer patients treated with ribociclib, abemaciclib, or palbociclib, compared with standard venous draws.

  Recruiting Institut Curie · Paris and 1 other locations · NCT07491380

• Screening and care for fear that breast or lung cancer will come back or get worse at Institut Curie

  This project will test brief screening methods to find people at Institut Curie with severe fear that their breast or lung cancer will come back or progress so they can get appropriate help.

  Recruiting Institut Curie · Paris · NCT07357311

• Tucatinib plus trastuzumab for HER3-mutant, HER2-not amplified metastatic breast cancer

  This trial will test whether combining tucatinib and trastuzumab helps people with metastatic or unresectable breast cancer whose tumors are HER2-negative but carry activating ERBB3 (HER3) mutations.

  Recruiting Phase 2 Institut Curie · Bordeaux and 8 other locations · NCT07193394

• Skin reactions from chest implantable port dressings

  This study will see how often dressings on chest implantable ports cause skin reactions in adults starting first-line chemotherapy.

  Recruiting Institut Curie · Paris and 2 other locations · NCT07158879

• PET-FAPI imaging to find pancreatic cancer earlier

  This will try a PET scan using a FAPI tracer to find early or returning pancreatic cancer in adults with recently diagnosed non‑metastatic PDAC who are enrolled in the HoMING cohort.

  Recruiting Phase 2 Institut Curie · Saint-Cloud · NCT06659705

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.